Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma

Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL). Different survival pathways, that is the Raf/MEK/Erk- or the p38MAPK cascade, have been suggested as downstream mediators of rituximab and may be involved in treatment failure. Biopsies from four pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wobser, M, Voigt, H, Eggert, A O, Houben, R, Kauczok, C S, Bröcker, E B, Becker, J C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359948/
https://www.ncbi.nlm.nih.gov/pubmed/17473827
http://dx.doi.org/10.1038/sj.bjc.6603762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359948/
https://www.ncbi.nlm.nih.gov/pubmed/17473827
http://dx.doi.org/10.1038/sj.bjc.6603762

Ejemplares similares